Loading…
Guangzhou drugmaker focused on children's medicines (cold, flu, digestive, skin) and chronic-disease drugs, with a gout drug in development.
Guangzhou drugmaker focused on children's medicines (cold, flu, digestive, skin) and chronic-disease drugs, with a gout drug in development.
Sells prescription drugs to hospitals and pharmacies in China, with a catalogue split between children's medicines for colds, flu, digestion and skin conditions and drugs for chronic diseases such as cardiovascular, kidney and liver illness. Its growth bet is AR882, a gout drug in development that has a US fast-track designation.
Moat: narrow (regulatory licence, brand). Many registered drug approvals, some on national reimbursement lists, with a pediatric focus.
Headquarters: Guangzhou, China · Founded: 2002 · Employees: 1,294
Size ApicHope Pharmaceutical (300723.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.99B, the 1274th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥29.78 on 6 Nov 2026.
Performance Over six months the shares fell 28.1%, against +1.9% for the median peer and -16.4% for the China market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue fell 28.3% over the last twelve months (peer median +11.7%); the operating margin is -50.2% (peer median 15.0%).
Valuation It trades at 25.7× forward earnings against a peer median of 23.1× (6th most expensive of 20).
Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is -11%, so the hurdle is +25 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 14.4 points below its cost of capital (8.6% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥735M | CN¥926M | CN¥1.44B | CN¥2.47B | CN¥2.25B |
| Revenue growth | — | -36% | -42% | +10% | — |
| Gross profit | CN¥443M | CN¥404M | CN¥735M | CN¥1.88B | CN¥1.86B |
| EBITDA | n/a | -CN¥94.7M | -CN¥63.4M | CN¥437M | CN¥408M |
| Net income | CN¥181M | -CN¥338M | -CN¥540M | CN¥185M | CN¥291M |
| Free cash flow | CN¥513M | -CN¥70.6M | -CN¥862M | CN¥133M | -CN¥114M |
| Capital expenditure | CN¥94.7M | CN¥127M | CN¥320M | CN¥334M | CN¥606M |
| Total debt | CN¥2.02B | CN¥2.12B | CN¥1.75B | CN¥825M | CN¥1.22B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| ApicHope Pharmaceutical 300723.SZ | $1.99B | -28% | -28% | -50% | 25.7× | 14.0% |
| China Resources Jiangzhong Pharmaceutical 600750.SS | $2.19B | -3% | -10% | 24% | 15.7× | -2.5% |
| Humanwell Healthcare (Group) 600079.SS | $4.71B | +3% | -3% | 16% | 13.4× | -6.8% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $49.7B | -6% | +6% | 27% | 36.4× | 14.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300723.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.3% | 0.0% | 7th lowest of 21 |
| 6-month return | -28.1% | +1.9% | 2nd lowest of 21 |
| Distance from 52-week high | -47.6% | -30.1% | 3rd lowest of 21 |
| Revenue growth (TTM) | -28.3% | +11.7% | lowest of 21 |
| Operating margin | -50.2% | 15.0% | 2nd lowest of 21 |
| Forward P/E | 25.7× | 23.1× | 6th most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | 14.0% | 6.0% | 7th most demanding of 18 |
| Growth delivered (Del g) | -11.0% | +8.2% | 2nd lowest of 18 |
| Hurdle (Req g minus delivered) | +24.9 pp | -0.2 pp | 4th most demanding of 18 |
| ROIC minus cost of capital | -14.4 pp | +0.0 pp | 3rd lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| ApicHope Pharmaceutical 300723.SZ | China | $1.99B | -28% | -28% | -50% | 25.7× | 14.0% | -11.0% |
| Sino Biological 301047.SZ | China | $1.98B | +50% | +20% | 17% | 63.8× | 36.8% | -15.1% |
| United Laboratories International 3933.HK | Hong Kong | $2.00B | -19% | -13% | 5% | 14.5× | 3.7% | +7.8% |
| BrightGene Bio-Medical Technology 688166.SS | China | $2.00B | -51% | +14% | 7% | 87.6× | 38.5% | +9.2% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $2.01B | -9% | -9% | 30% | 19.3× | 9.1% | +9.3% |
| Alembic Pharmaceuticals APLLTD.NS | India | $2.01B | +24% | +20% | 12% | 24.4× | 25.0% | +6.5% |
| Grand Pharmaceutical 0512.HK | Hong Kong | $2.01B | -27% | +7% | 13% | 9.8× | 1.2% | +14.1% |
| Qingdao Baheal Medical 301015.SZ | China | $2.02B | +4% | -6% | 8% | 23.5× | 11.9% | +5.0% |
| Shilpa Medicare SHILPAMED.NS | India | $1.95B | +113% | +28% | 21% | 62.1× | n/a | n/a |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.02B | +7% | +5% | 22% | 15.9× | -4.8% | +10.6% |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.95B | 0% | +13% | 27% | 13.0× | -0.5% | +16.7% |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.94B | -12% | +11% | 6% | 45.0× | n/a | n/a |
| Prestige Consumer Healthcare PBH | United States | $2.04B | -18% | -1% | 26% | 9.3× | -0.2% | +2.9% |
| Jinyu Bio-Technology 600201.SS | China | $2.04B | -15% | +22% | 10% | 62.4× | 24.4% | -2.4% |
| Harmony Biosciences HRMY | United States | $1.93B | +7% | +20% | 22% | 8.6× | -10.9% | +40.3% |
| Alivus Life Sciences ALIVUS.NS | India | $1.92B | +32% | +8% | 31% | 24.4× | 20.4% | +6.2% |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.92B | +28% | +15% | 31% | 24.6× | 29.3% | +15.7% |
| Shenyang Xingqi Pharmaceutical 300573.SZ | China | $1.91B | -25% | +17% | 33% | 13.7× | 6.0% | +29.1% |
| Maze Therapeutics MAZE | United States | $1.90B | +29% | +700% | -728% | n/a | n/a | n/a |
| Shenzhen Hepalink Pharmaceutical 9989.HK | Hong Kong | $1.89B | -18% | -1% | 8% | 8.3× | 0.4% | -0.2% |
| Harbin Pharmaceutical 600664.SS | China | $2.10B | +55% | +2% | 5% | 23.1× | -2.9% | +8.2% |